Q3 2022 Results

Company overview Financial performance Cardiovascular Ophthalmology Financial review 2022 priorities Innovation: Pipeline overview Immunology Neuroscience Global Health UNR844 - Reduction of disulfide bonds NCT04806503 READER (CUNR844A2022) Presbyopia Phase 2B Indication Phase Patients 225 Primary Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) Publication Characterize the dose response relationship among UNR844 doses 0 mg/mL, 5 mg/mL, 13.3 mg/mL, 23 mg/mL and 30 mg/mL dosed twice-daily after Month 3 of dosing. Change from baseline in Binocular distance- corrected near visual acuity at 40 cm at Month 3. 1:1 randomization - UNR844 0 mg/mL, 5 mg/mL, 13.3 mg/mL, 23 mg/mL and 30 mg/mL dosed twice-daily for three months Presbyopic participants aged 45 to 55 years 2022: Primary endpoint- when all patients have completed the 3 months treatment period (Actual) 2023: Final analysis -Study completion (all patients have completed 9 months pots treatment period) H1-2023 86 Investor Relations | Q3 2022 Results Appendix References Innovation: Clinical trials Abbreviations Oncology Other Biosimilars 1 NOVARTIS | Reimagining Medicine

View entire presentation